Supriya Lifescience Limited (NSE:SUPRIYA)
805.45
-6.25 (-0.77%)
Aug 21, 2026, 3:30 PM IST
Supriya Lifescience Revenue
Supriya Lifescience had revenue of 1.92B INR in the quarter ending June 30, 2026, with 32.62% growth. This brings the company's revenue in the last twelve months to 8.73B, up 28.14% year-over-year. In the fiscal year ending March 31, 2026, Supriya Lifescience had annual revenue of 8.28B with 18.86% growth.
Revenue (ttm)
8.73B
Revenue Growth
+28.14%
P/S Ratio
7.43
Revenue / Employee
16.94M
Employees
515
Market Cap
64.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.28B | 1.31B | 18.86% |
| Mar 31, 2025 | 6.96B | 1.26B | 22.12% |
| Mar 31, 2024 | 5.70B | 1.09B | 23.73% |
| Mar 31, 2023 | 4.61B | -691.11M | -13.04% |
| Mar 31, 2022 | 5.30B | 1.39B | 35.49% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 173.21B |
| Dishman Carbogen Amcis | 28.95B |
| Anthem Biosciences | 20.07B |
| OneSource Specialty Pharma | 15.43B |
| Concord Biotech | 11.08B |
| Blue Jet Healthcare | 8.86B |
| Panacea Biotec | 6.73B |
| Zota Health Care | 6.10B |